AMPK activation: a therapeutic target for type 2 diabetes?

QR Code

AMPK activation: a therapeutic target for type 2 diabetes?

Kimberly A Coughlan, Rudy J Valentine, Neil B Ruderman, Asish K Saha Endocrinology and Diabetes, Department of Medicine, Boston University Medical Center, Boston, MA, USA Abstract: Type 2 diabetes (T2D) is a metabolic disease characterized by insulin resistance, β-cell dysfunction, and el...

Full description

Saved in:

Bibliographic Details
Main Authors:	Coughlan KA, Valentine RJ, Ruderman NB, Saha AK
Format:	article
Language:	EN
Published:	Dove Medical Press 2014
Subjects:	Specialties of internal medicine RC581-951
Online Access:	https://doaj.org/article/ef61d514b1eb41c3b14a4bfaab5498d9
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
by: Michael A Via, et al.
Published: (2010)

SGLT2 inhibitors – an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
by: Seufert J
Published: (2015)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes &ndash; a review
by: Katrine B Hansen, et al.
Published: (2010)

Saxagliptin for type 2 diabetes
by: Antonio R Chacra, et al.
Published: (2010)

Sexual dysfunction in diabetic women: prevalence and differences in type 1 and type 2 diabetes mellitus
by: Mazzilli R, et al.
Published: (2015)

Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach
by: Kedia N
Published: (2011)

Impact of physical activity and bodyweight on health-related quality of life in people with type 2 diabetes
by: Eckert K
Published: (2012)

Type 2 diabetes in Brazil: epidemiology and management
by: Almeida-Pititto B, et al.
Published: (2015)

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus
by: Whaley JM, et al.
Published: (2012)

Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes
by: Mackenzie RWA, et al.
Published: (2014)

Disturbance of inorganic phosphate metabolism in diabetes mellitus: temporary therapeutic intervention trials
by: J&oslash;rn Ditzel, et al.
Published: (2009)

Linking obesity with type 2 diabetes: the role of T-bet
by: Wali JA, et al.
Published: (2014)

Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
by: Rigato M, et al.
Published: (2014)

Risk management in the treatment of type 2 diabetes with pioglitazone
by: Giuseppe Derosa, et al.
Published: (2009)

Metabolic abnormalities in pituitary adenoma patients: a novel therapeutic target and prognostic factor
by: Zheng X, et al.
Published: (2015)

Expression of gluconeogenic enzymes and 11β-hydroxysteroid dehydrogenase type 1 in liver of diabetic mice after acute exercise
by: Brust KB, et al.
Published: (2014)

Analog insulin detemir for patients with type 1 and type 2 diabetes: a review
by: Gregory E Peterson
Published: (2009)

Evidence for the benefit of exercise therapy in patients with type 2 diabetes
by: Madden KM
Published: (2013)

Insulin detemir for the treatment of obese patients with type 2 diabetes
by: Hollander PA
Published: (2012)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
by: Shannon A Miller, et al.
Published: (2009)

Red cell distribution width in type 2 diabetic patients
by: Nada AM
Published: (2015)

Fixed combination of repaglinide and metformin in the management of type 2 diabetes
by: Robert Moses
Published: (2009)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
by: Pamela Kushner
Published: (2010)

Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes
by: Henri K Parson, et al.
Published: (2010)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
by: Joshua J Neumiller, et al.
Published: (2010)

Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia
by: Anderson M, et al.
Published: (2014)

Saroglitazar for the treatment of hypertriglyceridemia in patients with type 2 diabetes: current evidence
by: Sosale A, et al.
Published: (2015)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
by: Kishimoto M
Published: (2013)

Sex differences in type 2 diabetes: focus on disease course and outcomes
by: Arnetz L, et al.
Published: (2014)

Emerging utility of once-weekly exenatide in patients with type 2 diabetes
by: Goud A, et al.
Published: (2015)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
by: Gallwitz B
Published: (2013)

Obesity and the development of type 2 diabetes: the effects of fatty tissue inflammation
by: Dara P Schuster
Published: (2010)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
by: Bo Ahr&eacute;n
Published: (2010)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
by: Holl, et al.
Published: (2014)

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
by: Jonathan K Reynolds
Published: (2009)

Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability
by: Nishio S, et al.
Published: (2015)

Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
by: Stanley S Schwartz
Published: (2010)

Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus
by: Feher M, et al.
Published: (2013)

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
by: Omoto S, et al.
Published: (2015)

Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
by: Paul Valensi
Published: (2009)